These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
563 related articles for article (PubMed ID: 20507799)
21. Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma. Soto-Perez-de-Celis E; Aguiar PN; Cordón ML; Chavarri-Guerra Y; Lopes GL J Natl Compr Canc Netw; 2019 Jun; 17(6):669-675. PubMed ID: 31200357 [TBL] [Abstract][Full Text] [Related]
22. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma. Simpson EL; Rafia R; Stevenson MD; Papaioannou D Health Technol Assess; 2010 May; 14 Suppl 1():63-7. PubMed ID: 20507805 [TBL] [Abstract][Full Text] [Related]
23. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303 [TBL] [Abstract][Full Text] [Related]
24. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Fleeman N; Bagust A; McLeod C; Greenhalgh J; Boland A; Dundar Y; Dickson R; Tudur Smith C; Davis H; Green J; Pearson M Health Technol Assess; 2010 May; 14 Suppl 1():47-53. PubMed ID: 20507803 [TBL] [Abstract][Full Text] [Related]
25. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database. Parikh ND; Marshall VD; Singal AG; Nathan H; Lok AS; Balkrishnan R; Shahinian V Hepatology; 2017 Jan; 65(1):122-133. PubMed ID: 27770556 [TBL] [Abstract][Full Text] [Related]
26. Telbivudine for the treatment of chronic hepatitis B infection. Hartwell D; Jones J; Harris P; Cooper K Health Technol Assess; 2009 Oct; 13 Suppl 3():23-30. PubMed ID: 19846025 [TBL] [Abstract][Full Text] [Related]
27. Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada. Muszbek N; Shah S; Carroll S; McDonald H; Dale P; Maroun J; Knox J Curr Med Res Opin; 2008 Dec; 24(12):3559-69. PubMed ID: 19032137 [TBL] [Abstract][Full Text] [Related]
28. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613 [TBL] [Abstract][Full Text] [Related]
29. Erlotinib for the treatment of relapsed non-small cell lung cancer. McLeod C; Bagust A; Boland A; Hockenhull J; Dundar Y; Proudlove C; Davis H; Green J; Macbeth F; Stevenson J; Walley T; Dickson R Health Technol Assess; 2009 Jun; 13 Suppl 1():41-7. PubMed ID: 19567213 [TBL] [Abstract][Full Text] [Related]
30. Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia. Dretzke J; Barton P; Kaambwa B; Connock M; Uthman O; Bayliss S; Meads C Health Technol Assess; 2010 Oct; 14(Suppl. 2):19-26. PubMed ID: 21047487 [TBL] [Abstract][Full Text] [Related]
31. Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck. Griffin S; Walker S; Sculpher M; White S; Erhorn S; Brent S; Dyker A; Ferrie L; Gilfillan C; Horsley W; Macfarlane K; Thomas S Health Technol Assess; 2009 Jun; 13 Suppl 1():49-54. PubMed ID: 19567214 [TBL] [Abstract][Full Text] [Related]
32. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113 [TBL] [Abstract][Full Text] [Related]
33. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. Zhu AX; Kudo M; Assenat E; Cattan S; Kang YK; Lim HY; Poon RT; Blanc JF; Vogel A; Chen CL; Dorval E; Peck-Radosavljevic M; Santoro A; Daniele B; Furuse J; Jappe A; Perraud K; Anak O; Sellami DB; Chen LT JAMA; 2014 Jul; 312(1):57-67. PubMed ID: 25058218 [TBL] [Abstract][Full Text] [Related]
34. Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma. Parikh ND; Singal AG; Hutton DW Cancer; 2017 Oct; 123(19):3725-3731. PubMed ID: 28662266 [TBL] [Abstract][Full Text] [Related]
35. Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal. Chilcott J; Lloyd Jones M; Wilkinson A Health Technol Assess; 2009 Jun; 13 Suppl 1():7-13. PubMed ID: 19567208 [TBL] [Abstract][Full Text] [Related]
36. Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. Fleeman N; Houten R; Bagust A; Richardson M; Beale S; Boland A; Dundar Y; Greenhalgh J; Hounsome J; Duarte R; Shenoy A Health Technol Assess; 2020 Jan; 24(2):1-180. PubMed ID: 31931920 [TBL] [Abstract][Full Text] [Related]
37. Entecavir for the treatment of chronic hepatitis B infection. Shepherd J; Gospodarevskaya E; Frampton G; Cooper K Health Technol Assess; 2009 Oct; 13 Suppl 3():31-6. PubMed ID: 19846026 [TBL] [Abstract][Full Text] [Related]
38. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge. Kim R; Byrne MT; Tan A; Aucejo F Oncology (Williston Park); 2011 Mar; 25(3):283-91, 295. PubMed ID: 21548473 [TBL] [Abstract][Full Text] [Related]
39. Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia. Walker S; Palmer S; Erhorn S; Brent S; Dyker A; Ferrie L; Horsley W; Macfarlane K; White S; Thomas S Health Technol Assess; 2009 Jun; 13 Suppl 1():35-40. PubMed ID: 19567212 [TBL] [Abstract][Full Text] [Related]
40. Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice? Sacco R; Bargellini I; Ginanni B; Bertini M; Faggioni L; Federici G; Romano A; Bertoni M; Metrangolo S; Altomare E; Parisi G; Tumino E; Scaramuzzino A; Bresci G; Bartolozzi C Expert Rev Anticancer Ther; 2012 Jul; 12(7):869-75. PubMed ID: 22845401 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]